SecBot SecBot

KTTAW

Pasithea Therapeutics Corp.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001841330 Biotech & Drug Discovery
Former ticker of Pasithea Therapeutics Corp. · KTTA stock page →
—
Market cap
$93.6K
Nano cap
1 year
−43.5%
from $0.7080 · Oct 27
30 days
−16.7%
from $0.4800
52-week range
$0.2920–1.47
−73% from high · low Nov 21
Avg volume 20D
251.6K
Oct 23 spike 1.53M
Short interest
26.8K
≈0.1% of shares · −1.5%
Days to cover
3.3
at average volume
Filing reports
2
analyzed by SecBot
SecBot read BEARISH 1 report · 90 days
Balance 1 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest BEARISH Pasithea Therapeutics received a 180-day extension from Nasdaq, moving the deadline to regain compliance…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest −1.5% to 26.8K shares. 3.3 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F
Top holderSharesValue
Marex Group Ltd25,000$223.00
SUSQUEHANNA INTERNATIONAL GROUP, LLP24,293$216.00
Clear Street Group Inc.380$3.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 Listing status
Delisted: KTTAW — removed from the Nasdaq symbol directory
Pasithea Therapeutics Corp. - Warrant
Aug 21, 2026 SEC
Pasithea Therapeutics received a 180-day extension from Nasdaq, moving the deadline to regain compliance with the…
8-K — Impact 7/10
May 4, 2026 SEC
Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer effective May 1, 2026, and granted…
8-K — Impact 2/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 15, 2026
26,825
shares short
-1.5%
vs prior settlement
3.3
days to cover
≈0.1%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 17, 2026
Listing
Delisted: KTTAW — removed from the Nasdaq symbol directory
Pasithea Therapeutics Corp. - Warrant
Sep 14, 2026
FDA
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Tx to Present Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at 2026 European NF Conference
Jul 21, 2026
Press release
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Jul 8, 2026
Press release
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit on July 16 in Boston
Jun 16, 2026
Press release
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

SecBot reports

2 filings · 0 bullish · 1 bearish · 1 neutral
All KTTAW filing & press-release reports (2)